Siegfried Reich, P.H.D

2021

In 2021, Siegfried Reich, P.H.D earned a total compensation of $4M as Executive Vice President and Chief Scientific Officer at Turning Point Therapeutics, a 31% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$216,215
Option Awards$1,662,593
Salary$417,000
Stock Awards$1,658,418
Other$11,600
Total$3,965,826

PHD received $1.7M in option awards, accounting for 42% of the total pay in 2021.

PHD also received $216.2K in non-equity incentive plan, $417K in salary, $1.7M in stock awards and $11.6K in other compensation.

Rankings

In 2021, Siegfried Reich, P.H.D's compensation ranked 3,383rd out of 12,415 executives tracked by ExecPay. In other words, PHD earned more than 72.8% of executives.

ClassificationRankingPercentile
All
3,383
out of 12,415
73rd
Division
Manufacturing
1,373
out of 5,505
75th
Major group
Chemicals And Allied Products
557
out of 2,375
77th
Industry group
Drugs
496
out of 2,096
76th
Industry
Pharmaceutical Preparations
344
out of 1,546
78th
Source: SEC filing on April 29, 2022.

PHD's colleagues

We found six more compensation records of executives who worked with Siegfried Reich, P.H.D at Turning Point Therapeutics in 2021.

2021

Athena Countouriotis

Turning Point Therapeutics

Chief Executive Officer

2021

Mohammad Hirmand

Turning Point Therapeutics

Chief Medical Officer

2021

Annette North

Turning Point Therapeutics

General Counsel

2021

Paolo Tombesi

Turning Point Therapeutics

Chief Financial Officer

2021

Yi Larson

Turning Point Therapeutics

Chief Financial Officer

2021

Brian Baker

Turning Point Therapeutics

Former Senior Vice President, Finance and Administration

News

You may also like